Variant · Snv
MTOR R2152C
CI-VAR-00003768Explore in graph →CIViC 3439
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24631838
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Unmapped disease1unmapped disease | ||||||||
| MTOR R2152C | (functional) | Functional | D | Supports Unaltered Function | 2 | accepted | EID9556Functional analysis of the mTOR R2152C mutation was performed in HEK-293T cells co-transfected with HA-GST-S6K1. Immunoblots showed R2152C resulted in similar low level of S6K1 phosphorylation as wild… (full text at CIViC) PMID 24631838 · Grabiner et al., 2014 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available